Stressmarq has developed active alpha synuclein pre-formed fibrils (PFFs) that can induce endogenous alpha synuclein phosphorylation and Lewy body formation in vitro and in vitro. These fibrils seed the formation of new fibrils from active alpha synuclein monomers.
Type 1 human and mouse preformed fibrils (PFFs) and monomers have been tested in cell culture assays and thioflavin T assays. Human and mouse PFFs have been tested in vivo and produced alpha synuclein pathology in rat brains within 30 days of injection. A53T alpha synuclein monomers and PFFs are also available. The A53T mutation has been linked to early-onset Parkinson’s Disease and increased alpha synuclein fibrillization.
Alpha synuclein oligomers are increasingly thought to be the toxic species in synucleinopathies. Small molecules can be used to stabilize alpha synuclein in its oligomeric forms, preventing further aggregation into fibrils.
StressMarq is in the process of developing new types of fibrils as well as thoroughly characterizing our current products. They currently have several types of alpha synuclein proteins available.